- All sites activated with 38 patients dosed in the potentially pivotal Phase 2 clinical study, FIRCE-1 of firicabtagene autoleucel ( firi-cel) - - Completed $110 million private placement equity financing, extending cash runway through 2026 - SAN CARLOS, Calif., Aug.
Ongoing Phase 1 study informed dose selection for CARGO’s currently enrolling, potentially pivotal Phase 2 clinical study, FIRCE-1 of firicabtagene autoleucel (firi-cel) 1 , in patients with relapsed or refractory (R/R) large B-cell lymphoma (LBCL) Notable patient subset analyses show durability of
– Appointment adds strategic finance and broad operating experience to Board as Company advances potentially pivotal Phase 2 clinical study for CAR T-cell therapy candidate, firicabtagene autoleucel (firi-cel) – SAN CARLOS, Calif., June 04, 2024 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc.
SAN CARLOS, Calif., May 28, 2024 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (NASDAQ: CRGX), a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients, today announced that the company will be participating in the
– Financing includes participation from new and existing investors – – Supports BLA preparation for potentially pivotal Phase 2 study, FIRCE-1 of firicabtagene autoleucel (firi-cel) (CRG-022) and IND-enabling studies for CRG-023 – – Extends cash runway through 2026 – SAN CARLOS, Calif., May 28,
- 26 sites activated and over 20 patients dosed in the potentially pivotal Phase 2 clinical study, FIRCE-1 of firicabtagene autoleucel ( firi-cel) (CRG-022); Currently on-track for interim results expected in 1H25 - - Independent Data Monitoring Committee (IDMC) recommended continuation of FIRCE-1
– Appointment adds oncology and cell therapy clinical development expertise to Board as Company continues late-stage development of its lead CAR T-cell therapy candidate, firi-cel (CRG-022) – SAN MATEO, Calif., April 15, 2024 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc.
– Potentially pivotal Phase 2 clinical study FIRCE-1 of firicabtagene autoleucel (CRG-022) is rapidly recruiting with 20 sites open to date; interim results expected 1H 2025 – SAN MATEO, Calif., March 21, 2024 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc.
SAN MATEO, Calif., Feb. 29, 2024 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (NASDAQ: CRGX), a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients, today announced that the company will participate in the 44 th Annual
SAN MATEO, Calif., Jan. 03, 2024 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (NASDAQ: CRGX), a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients, today announced that the company will participate in the 42nd Annual